Replies to post #779253 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

Zadie420,

Direct as improved likely is good enough in its own in most solid tumor cases but there is synergy between intratumoral DC treatment and intradermal DC treatment as intradermal sets up systemic, whole body surveillance quickly to prevent additional metastasis while intratumoral sets up on site treatment that develops into broader systemic immune memory over a little more time. Best wishes.

[Chiugray]

Zadie, There may be nuances with using L or Direct, vs using both, to treat an individual cancer patient, but I think in the future, practically, you will only need DCVax-Direct, not both. Direct and L will both have the superior cancer vaccine qualities that no other drug has, but Direct will just be the next-gen product. I say practically as I am also factoring in the cost and time to first-dosing factors.

Just playing around with some broad strokes and thoughts:

DCVax-Direct is roughly 4X better than DCVax-L
- Costs reduced by 2X (no surgery, no lysate processing)
- Time reduced by 2X (fewer steps)
- Simpler

Why
- No surgery (no tumor lysate to obtain antigens, saves cost and time)
- Fewer DC mfg steps (no ex vivo lysate to DC antigen loading, maturing)
- Direct may be just ~3 weeks from cancer diagnosis to first-dosing
- Time is short enough that chemo/radiation might not be needed
- As opposed to L's time to first-dosing is longer (so would doctors do chemo, tbd?)
- If no chemo, that saves ~6 weeks, money, side effects, drugs management, and recovery

Earlier and simpler should improve overall costs, therapeutic results, and quality of life.